Crystec Pharma

Executive Summary

Crystec Pharma is a London-based drug delivery company leveraging its proprietary mSAS® supercritical fluid platform to enhance the bioavailability, stability, and delivery of small and large molecule therapeutics. Founded in 2016, the company operates at the preclinical to early clinical stage, focusing on partnerships with pharmaceutical firms to reformulate drugs with poor solubility or stability. While financial details and specific pipeline assets remain undisclosed, Crystec's technology has broad applicability across CNS, oncology, and chronic disease therapies. The company's private status and limited public profile suggest a strategic focus on out-licensing and collaborative development rather than independent clinical advancement. Key risks include dependence on third-party partners and the competitive landscape for formulation technologies.

Upcoming Catalysts (preview)

• Q3 2026Announcement of a major pharma partnership for mSAS-based formulation40% success
• Q4 2026First preclinical data readout from a partnered program demonstrating improved oral bioavailability50% success
• Q2 2026Series A or B funding round to expand mSAS manufacturing capacity60% success